Pharming Group Balance Sheet Health
Financial Health criteria checks 5/6
Pharming Group has a total shareholder equity of $220.9M and total debt of $90.5M, which brings its debt-to-equity ratio to 40.9%. Its total assets and total liabilities are $415.9M and $195.0M respectively.
Key information
40.9%
Debt to equity ratio
US$90.47m
Debt
| Interest coverage ratio | n/a |
| Cash | US$160.32m |
| Equity | US$220.94m |
| Total liabilities | US$194.99m |
| Total assets | US$415.93m |
Recent financial health updates
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Feb 20Recent updates
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Feb 20Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price
Oct 29Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly
Jun 03Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)
May 12Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?
Mar 15Financial Position Analysis
Short Term Liabilities: PHARM's short term assets ($270.6M) exceed its short term liabilities ($79.9M).
Long Term Liabilities: PHARM's short term assets ($270.6M) exceed its long term liabilities ($115.1M).
Debt to Equity History and Analysis
Debt Level: PHARM has more cash than its total debt.
Reducing Debt: PHARM's debt to equity ratio has reduced from 76% to 40.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHARM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PHARM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.